FIF Funding for Diabeto, ORamaVR and Impaakt
Summary
The FIF is the mechanism that aims to foster innovation and the scale up of promising companies from Geneva at the service of the United Nations (UN) Sustainable Development Goals (SDGs). Three new start-ups secured FIF support: Diabeto is a biopharmaceutical start-up project spinning off the University of Geneva and based on pioneering expertise in discovery of mechanisms sustaining life without insulin. Its first mission is to advance the preclinical and clinical development of a first-in-class breakthrough therapeutic solution to improve treatment of type-1 diabetic patients. This platform empowers institutions and developers to massively create high fidelity medical VR simulations eight times faster and for one eighth of the cost relative to current industry standards. By attributing an impact score based on factual data and analyses, Impaakt delivers reliable, unbiased information to guide investors and consumers on who to spend with, invest in or advocate for.